Biotherapeutic effects of Bifidobacterium spp. on orogastric and systemic candidiasis in immunodeficient mice

Revista Iberoamericana de Micologia

Volumn 15, Issue 4, 1998, Pages 265-270

  Doug Wagner, R ^a   Warner, Thomas ^a   Pierson, Carey ^a   Roberts, Lisa ^a   Farmer, Jeffery ^a   Dohnalek, Margaret ^b   Hilty, Milo ^b   Balish, Edward ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Bifidobacterium; Candidiasis; Immunodeficient mice; Probiotics

Indexed keywords

EID: 0000802754     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Tahara T, Oshimura M, Umezawa C, Kanatani K. Isolation, partial characterization, and mode of action of acidocin J1132, a two-component bacteriocin produced by Lactobacillus acidophilus JCM 1132. Appl Environ Microbiol 1996; 62: 892-897.
2. Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35: 483-489.
3. Coconnier, MH, Bernet MF, Chauviere G, Servin AL. Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis Res 1993; 11: 235-242.
4. Miettinen M, Vuopio-Varkila J, Varkila K. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infect Immun 1996; 64: 5403-5405.
5. Shiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1995; 78: 491-497.
6. Wagner RD, Warner T, Roberts L, Farmer J, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 1997; 65: 3345-3351.
7. Wagner RD, Pierson C. Warner T, Balish E. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice. Infect Immun 1997; 65: 4165-4172.
8. Elmer GW, Surawicz CM, McFariand LV. Biotherapeutic agents a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 1996; 275: 870-876.
9. Fuller R. Probiotics in human medicine. Gut 1991; 32: 439-442.
10. De Simone C, Ciardi A, Grassi A. et al. Effect of Bifidobacterium bifidum and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes. Immunopharmacol immunotoxicol 1992; 14: 331-340.
11. Korschunov VM, Smeyanov W, Efimov BA, Tarabrina NP, Ivanov AA, Baranov AE. Therapeutic use of an antibiotic-resistant Bifidobacterium preparation in men exposed to high-dose γ-irradiation. J Med Microbiol 1996; 44: 70-74.
12. Colombel JF, Cortot A, Neut C, Romond C. Yogurt with Bifidobacterium longum reduces erythromycin-induced GI effects. Lancet 1987; 2: 43.
13. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344: 1046-1049.
14. Yasui H, Kiyoshima, Ushijima H. Passive protection against rotavirus-induced diarrhea of mouse pups born to and nursed by dams fed Bifidobacterium breve YIT4064. J Infect Dis 1995; 172: 403-409.
15. Kmet V, Kmetova M, Contrepois M, Ribot Y. Bifidobacteria and Escherichia coli translocation in gnotobiotic mice. In: Mestecky J, Russell MW, Jackson S, Michalek SM, Hogenov HT, Sterzl J (Eds.) Advances in mucosal immunology, Vol. 371. New York, Plenum Press, 1995: 479-482.
16. Sekine K, Watanabe-Sekine E, Toida T, Kasashima T, Kataoka T, Hasnimoto Y. Adjuvant activity of the cell wall of Bifidobacterium infantis for in vivo immune responses in mice. Immunopharmacol Immunotoxicol 1994; 16: 589-609.
17. Yasui H, Ohwaki M. Enhancement of immune response in Peyer's patch cells cultured with Bifidobacterium breve. J Dairy Sci 1991; 4: 1187-1195.
18. Meile L, Ludwig W, Rueger U, et al. Bifidobacterium lactis sp. nov., a moderately oxygen tolerant species isolated from fermented milk. System Appl Microbiol 1997; 20: 57-64.
19. Cantoma MT, Balish E. Role of CD4+ lymphocytes in resistance to mucosal candidiasis. Infect Immun 1991; 59: 2447-2435.
20. De Petrino SF, De Jorrat MEBB, Meson O, Perdigon G. Protective ability of certain lactic acid bacteria against an infection with Candida albicans in a mouse immunosuppression model by corticoid. Food Ag Immunol 1995; 7: 365-373.
21. Hudault S, Bridonneau C, Raibaud P, Chabanet C, Vial MF. Relationship between intestinal colonization of Bifidobacterium bifidum in infants and the presence of exogenous and endogenous growth-promoting factors in their stools. Pediatr Res 1994; 35: 696-700.
22. Marcon M. (Children's Hospital, Columbus, Ohio). Personal communication.
23. Berg R, Bemasconi P, Fowler D, Gautreaux M. Inhibition of Candida albicans translocation from the Gl tract of mice by oral administration of Saccharomyces boulardil. J Infect Dis 1993; 168: 1314-1318.
24. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics J Nutr 1995; 125: 1401-1412.
25. Lee Y-K, Salminen 3. The coming of age of probiotics. Trends Food Sci Technol 1995; 6: 241-245.